Literature DB >> 26256403

Discovery and structural optimization of 1-phenyl-3-(1-phenylethyl)urea derivatives as novel inhibitors of CRAC channel.

Hai-zhen Zhang1, Xiao-lan Xu2, Hua-yan Chen1, Sher Ali2, Dan Wang2, Jun-wei Yu2, Tao Xu2, Fa-jun Nan1.   

Abstract

AIM: Ca(2+)-release-activated Ca(2+) (CRAC) channel, a subfamily of store-operated channels, is formed by calcium release-activated calcium modulator 1 (ORAI1), and gated by stromal interaction molecule 1 (STIM1). CRAC channel may be a novel target for the treatment of immune disorders and allergy. The aim of this study was to identify novel small molecule CRAC channel inhibitors.
METHODS: HEK293 cells stably co-expressing both ORAI1 and STIM1 were used for high-throughput screening. A hit, 1-phenyl-3-(1-phenylethyl)urea, was identified that inhibited CRAC channels by targeting ORAI1. Five series of its derivatives were designed and synthesized, and their primary structure-activity relationships (SARs) were analyzed. All derivatives were assessed for their effects on Ca(2+) influx through CRAC channels on HEK293 cells, cytotoxicity in Jurkat cells, and IL-2 production in Jurkat cells expressing ORAI1-SS-eGFP.
RESULTS: A total of 19 hits were discovered in libraries containing 32 000 compounds using the high-throughput screening. 1-Phenyl-3-(1-phenylethyl)urea inhibited Ca(2+) influx with IC50 of 3.25±0.17 μmol/L. SAR study on its derivatives showed that the alkyl substituent on the α-position of the left-side benzylic amine (R1) was essential for Ca(2+) influx inhibition and that the S-configuration was better than the R-configuration. The derivatives in which the right-side R3 was substituted by an electron-donating group showed more potent inhibitory activity than those that were substituted by electron-withdrawing groups. Furthermore, the free N-H of urea was not necessary to maintain the high potency of Ca(2+) influx inhibition. The N,N'-disubstituted or N'-substituted derivatives showed relatively low cytotoxicity but maintained the ability to inhibit IL-2 production. Among them, compound 5b showed an improved inhibition of IL-2 production and low cytotoxicity.
CONCLUSION: 1-Phenyl-3-(1-phenylethyl)urea is a novel CRAC channel inhibitor that specifically targets ORAI1. This study provides a new chemical scaffold for design and development of CRAC channel inhibitors with improved Ca(2+) influx inhibition, immune inhibition and low cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26256403      PMCID: PMC4561970          DOI: 10.1038/aps.2015.52

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  27 in total

1.  The calcium store sensor, STIM1, reciprocally controls Orai and CaV1.2 channels.

Authors:  Youjun Wang; Xiaoxiang Deng; Salvatore Mancarella; Eunan Hendron; Satoru Eguchi; Jonathan Soboloff; Xiang D Tang; Donald L Gill
Journal:  Science       Date:  2010-10-01       Impact factor: 47.728

Review 2.  Immunodeficiency due to defects in store-operated calcium entry.

Authors:  Stefan Feske
Journal:  Ann N Y Acad Sci       Date:  2011-11       Impact factor: 5.691

3.  Graded activation of CRAC channel by binding of different numbers of STIM1 to Orai1 subunits.

Authors:  Zhengzheng Li; Lin Liu; Yongqiang Deng; Wei Ji; Wen Du; Pingyong Xu; Liangyi Chen; Tao Xu
Journal:  Cell Res       Date:  2010-09-14       Impact factor: 25.617

Review 4.  Genetic polymorphisms in Kawasaki disease.

Authors:  Ho-chang Kuo; Wei-chiao Chang
Journal:  Acta Pharmacol Sin       Date:  2011-09-05       Impact factor: 6.150

Review 5.  Ca(2+) release-activated Ca(2+) channel inhibitors.

Authors:  Paolo Pevarello; Silvia Cainarca; Chiara Liberati; Paola Tarroni; Francesco Piscitelli; Elda Severi
Journal:  Pharm Pat Anal       Date:  2014-03

6.  A pyrazole derivative, YM-58483, potently inhibits store-operated sustained Ca2+ influx and IL-2 production in T lymphocytes.

Authors:  Jun Ishikawa; Keiko Ohga; Taiji Yoshino; Ryuichi Takezawa; Atsushi Ichikawa; Hirokazu Kubota; Toshimitsu Yamada
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

7.  Potentiation and inhibition of Ca(2+) release-activated Ca(2+) channels by 2-aminoethyldiphenyl borate (2-APB) occurs independently of IP(3) receptors.

Authors:  M Prakriya; R S Lewis
Journal:  J Physiol       Date:  2001-10-01       Impact factor: 5.182

Review 8.  Mast cell CRAC channel as a novel therapeutic target in allergy.

Authors:  Joseph L Di Capite; Grant J Bates; Anant B Parekh
Journal:  Curr Opin Allergy Clin Immunol       Date:  2011-02

Review 9.  Calcium in tumour metastasis: new roles for known actors.

Authors:  Natalia Prevarskaya; Roman Skryma; Yaroslav Shuba
Journal:  Nat Rev Cancer       Date:  2011-07-22       Impact factor: 60.716

10.  Gated regulation of CRAC channel ion selectivity by STIM1.

Authors:  Beth A McNally; Agila Somasundaram; Megumi Yamashita; Murali Prakriya
Journal:  Nature       Date:  2012-01-25       Impact factor: 49.962

View more
  4 in total

Review 1.  Store-operated CRAC channel inhibitors: opportunities and challenges.

Authors:  Chengsen Tian; Lupei Du; Yubin Zhou; Minyong Li
Journal:  Future Med Chem       Date:  2016-05-05       Impact factor: 3.808

2.  Ultrasonic-assisted-synthesis of isoindolin-1-one derivatives.

Authors:  Muhammad Idham Darussalam Mardjan; Muhamad Fadhly Hariadi; Indah Mutiara Putri; Nilna Amalia Musyarrofah; Muflihah Salimah; Bambang Purwono; Laurent Commeiras
Journal:  RSC Adv       Date:  2022-06-29       Impact factor: 4.036

Review 3.  Structural Mechanisms of Store-Operated and Mitochondrial Calcium Regulation: Initiation Points for Drug Discovery.

Authors:  Megan Noble; Qi-Tong Lin; Christian Sirko; Jacob A Houpt; Matthew J Novello; Peter B Stathopulos
Journal:  Int J Mol Sci       Date:  2020-05-21       Impact factor: 5.923

Review 4.  Pharmacological blockade of KV1.3 channel as a promising treatment in autoimmune diseases.

Authors:  Carlos A Cañas; Santiago Castaño-Valencia; Fernando Castro-Herrera
Journal:  J Transl Autoimmun       Date:  2022-01-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.